BNGO · Bionano Genomics, Inc. · Financials
$1.58
+0.02 (+1.29%)
At close · Oct 1
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has prepared cash flows forecasts which indicate that based on the Company’s expected operating losses and negative cash flows, there is substantial doubt about the Company’s ability to continue as a going concern within twelve months after the date that the unaudited condensed consolidated financial statements for the six months ended June 30, 2026, are issued.”View the 10-Q filed Aug 10, 2026
Market Cap
$20.37M
Shares
11.78M
Volume · Oct 1
218.43K
Avg daily vol (3M)
910.17K
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$28.51M
-7.4%
FY2025
Net Income
-$26.4M
+76.4%
FY2025
Gross Margin
46.25%
+45pp
FY2025
Operating Margin
-116.95%
+220.9pp
FY2025
Diluted EPS
-$4.85
+94.5%
FY2025
Operating Cash Flow
-$16.35M
+76.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $31M – $33M | $30.18M | $28.51M | $30.78MG | $36.12MG | $27.8M | $17.98M | $8.5M | $10.13M | $12M | $9.51M | |
| — | $15.84M | $15.32M | $30.4M | $26.55M | $21.86M | $14.11M | $5.73M | $6.77M | $8.71M | $6.03M | |
| — | $14.34M | $13.19M | $380K | $9.57M | $5.95M | $3.87M | $2.77M | $3.36M | $3.29M | $3.47M | |
| — | — | 46.25% | 1.23% | 26.49% | 21.38% | 21.54% | 32.61% | 33.18% | 27.41% | 36.55% | |
| — | $12.2M | $11.37M | $24.8M | $54.03M | $49.05M | $22.49M | $10.26M | $9.08M | $9.48M | $12.01M | |
| — | $34.33M | $35.15M | $51.86M | $92.76M | $88.6M | $58.49M | $31.07M | $20.16M | $14.22M | $14.08M | |
| — | — | $5.4M | $6.6M | $7.2M | $5.8M | $1.4M | $100K | — | — | — | |
| — | $9.32M | $9.53M | $14.02M | $13.71M | $9.62M | $3.35M | $1.48M | $1.13M | $1.32M | $1.5M | |
| — | — | $0 | — | — | — | — | — | — | — | — | |
| — | $46.53M | $46.52M | $104.36M | $224.81M | $137.64M | $80.98M | $41.32M | $29.24M | $23.7M | $26.69M | |
| — | -$32.19M | -$33.34M | -$103.98M | -$215.25M | -$131.7M | -$77.1M | -$38.55M | -$25.87M | -$20.42M | -$23.22M | |
| — | — | -116.95% | -337.87% | -595.98% | -473.7% | -428.79% | -453.38% | -255.44% | -170.12% | -244.28% | |
| — | -$22.87M | -$23.81M | -$89.96M | -$201.54M | -$122.08M | -$73.75M | -$37.07M | -$24.75M | -$19.09M | -$21.71M | |
| — | $5.17M | — | — | $5.12M | $298K | $927K | $2.52M | $2.29M | $1.38M | $590.93K | |
| — | — | $1M | $1.5M | $3.3M | $1.5M | $400K | — | — | — | — | |
| — | $94K | $7.01M | -$8M | -$17.19M | $986K | -$1.05M | -$2.53M | -$3.92M | $1.93M | -$128K | |
| — | -$32.1M | -$26.33M | -$111.98M | -$232.43M | -$130.71M | -$78.15M | -$41.08M | -$29.79M | -$18.48M | -$23.35M | |
| — | $67K | $67K | $33K | $62K | $1.88M | -$5.72M | $29K | $21.05K | $15.51K | $18.55K | |
| — | -$32.16M | -$26.4M | -$112.02M | -$232.49M | -$132.6M | -$72.44M | -$41.11M | -$29.82M | -$18.5M | -$23.37M | |
| — | — | -92.59% | -363.98% | -643.74% | -476.93% | -402.84% | -483.43% | -294.34% | -154.13% | -245.82% | |
| — | -$32.14M | -$26.41M | -$112.01M | -$231.35M | -$133.18M | -$72.97M | -$41.11M | — | — | — | |
| USD/shares | — | -$3.11 | -$4.85 | -$88.13 | -$408.60 | -$274.80 | -$156.00 | — | — | — | — |
| USD/shares | — | -$3.11 | -$4.85 | -$88.13 | -$408.60 | -$274.80 | -$156.00 | — | — | — | — |
| shares | — | — | 5.45M | 1.27M | 569K | 482.02K | 461.3K | 173.75K | 24.96K | 11.8K | 4501.775 |
| shares | — | — | 5.45M | 1.27M | 569K | 482.02K | 461.3K | 173.75K | 24.96K | 11.8K | 4501.775 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 0.76×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 11 similar-size Medical Instruments & Supplies companies (of 47 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $28,508,000 | $30,776,000 | $36,116,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| EMEA | $14,108,000 | $14,234,000 | $12,963,000 | $8,960,000 | $5,604,000 | $3,163,000 | $3,627,602 |
| Americas | $12,180,000 | $13,649,000 | $18,020,000 | $13,862,000 | $9,329,000 | — | — |
| Asia Pacific | $2,220,000 | $2,893,000 | $5,133,000 | $4,980,000 | $3,048,000 | $851,000 | $1,471,639 |
| North America | — | — | — | — | — | $4,489,000 | $5,030,267 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Consumable Revenue | $13,970,000 | $12,773,000 | $11,157,000 | $6,731,000 | $5,808,000 | $3,145,000 | $2,711,981 |
| Software Revenue | $6,410,000 | $6,192,000 | $5,571,000 | $5,127,000 | $991,000 | — | — |
| Instrument Revenue | $6,363,000 | $8,043,000 | $9,999,000 | $8,567,000 | $5,887,000 | $3,085,000 | $6,762,463 |
| Product And Service Other | $1,765,000 | $3,768,000 | $9,389,000 | $7,377,000 | $5,295,000 | $2,273,000 | $655,064 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -$33,339,000 | -$103,983,000 | -$215,245,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -116.9% | -337.9% | -596% |